Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) has received a consensus rating of “Reduce” from the six research firms that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $1.43.
Several analysts recently commented on the stock. The Goldman Sachs Group cut their price objective on shares of Ginkgo Bioworks from $0.02 to $0.01 and set a “sell” rating on the stock in a research report on Tuesday, July 9th. BTIG Research raised their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a research report on Friday, August 23rd.
Check Out Our Latest Research Report on Ginkgo Bioworks
Institutional Investors Weigh In On Ginkgo Bioworks
Ginkgo Bioworks Stock Performance
Shares of NYSE DNA opened at $6.23 on Tuesday. The company has a 50 day simple moving average of $2.59 and a two-hundred day simple moving average of $0.93. Ginkgo Bioworks has a fifty-two week low of $5.26 and a fifty-two week high of $82.80. The company has a market capitalization of $13.77 billion, a price-to-earnings ratio of -14.15 and a beta of 1.06.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). Ginkgo Bioworks had a negative return on equity of 63.09% and a negative net margin of 486.98%. The company had revenue of $56.21 million during the quarter, compared to analyst estimates of $41.46 million. On average, analysts forecast that Ginkgo Bioworks will post -12.6 earnings per share for the current fiscal year.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
- Five stocks we like better than Ginkgo Bioworks
- Top Biotech Stocks: Exploring Innovation Opportunities
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Why Are These Companies Considered Blue Chips?
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.